Domain Therapeutics has named Youssef Bennani as chairman of the company’s board, taking over from Sam Eletr.
Bennani currently serves as site head and VP of R&D at Vertex Pharmaceuticals’ site in Laval, Quebec. Prior to this, he spent seven years as VP of drug innovation at Vertex .
“Dr Bennani joins us at a time when we intend to strengthen our role as a pharma industry partner and expand our internal pipeline,” said Pascal Neuville, board director and CEO of Domain.
This pipeline includes new drug candidates targeting G protein-coupled receptors. Domain has several partnerships involving these products, including one with Merck Serono in Parkinson’s disease.